BioCentury | Aug 28, 2020
Emerging Company Profile

Concarlo: targeting proliferation and resistance in one go

...targeting the interaction domain between p27 and PTK6...
...CDKN1B) – cyclin-dependent kinase inhibitor 1BPTK6protein tyrosine kinase 6 Virginia...
BioCentury | Oct 26, 2019
Product Development

How a KRAS program transformed Mirati's story

With the first clinical data due on Mirati’s KRAS inhibitor next week, the market will get its first chance to justify -- or otherwise -- the large chunk of the company’s $3 billion valuation tied...
BioCentury | Aug 1, 2019
Distillery Therapeutics

A pyrrolopyrimidine-based TYRO3 inhibitor for primary effusion lymphoma

DISEASE CATEGORY: Cancer INDICATION: Non-Hodgkin lymphoma (NHL) A UNC Chapel Hill team identified a pyrrolopyrimidine-based inhibitor of TYRO3 that could treat the primary effusion lymphoma (PEL), an NHL subtype. TYRO3 mRNA levels were higher in...
BioCentury | Jul 3, 2019
Preclinical News

Controlling CAR T toxicity with BMS's Sprycel

Bristol-Myers Squibb’s leukemia drug Sprycel could stop CAR T associated cytokine release syndrome at the root without the need for engineered control features like off-switches. One of the main limitations of CAR T cell therapy...
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
BioCentury | Feb 8, 2019
Company News

BioMotiv, Rutgers launch TamRx

Cancer immunotherapy company TamRx LLC (Cleveland, Ohio) launched Feb. 7 from pharmaceutical accelerator BioMotiv LLC (Cleveland, Ohio), shooting to reach the clinic with its pan-TAM inhibitors in 2021. The company is based on research from...
BioCentury | Feb 7, 2019
Company News

BioMotiv, Rutgers launch TamRx

Cancer immunotherapy company TamRx LLC (Cleveland, Ohio) launched Thursday from pharmaceutical accelerator BioMotiv LLC (Cleveland, Ohio), shooting to reach the clinic with its pan-TAM inhibitors in 2021. The company is based on research from Rutgers...
BioCentury | Oct 26, 2018
Clinical News

Mirati reports updated confirmed ORR of 16% in Phase II of sitravatinib for NSCLC

Mirati Therapeutics Inc. (NASDAQ:MRTX) reported data from 56 evaluable patients with checkpoint-refractory non-small cell lung cancer in a Phase II trial showing that its once-daily oral receptor tyrosine kinase (RTK) inhibitor sitravatinib (MGCD516) plus PD-1...
BioCentury | Oct 22, 2018
Clinical News

Mirati falls on updated response data for sitravatinib in NSCLC

Mirati Therapeutics Inc. (NASDAQ:MRTX) reported data Monday from 56 evaluable patients with checkpoint-refractory non-small cell lung cancer in a Phase II trial showing that its once-daily oral receptor tyrosine kinase (RTK) inhibitor sitravatinib (MGCD516) plus...
BioCentury | Oct 2, 2018
Company News

FDA approves Paratek antibiotics

Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) received a pair of FDA approvals Tuesday for Nuzyra omadacycline and Seysara sarecycline. The agency approved Nuzyra to treat community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections...
Items per page:
1 - 10 of 144